Precision BioSciences Receives Two Patent Allowances
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 hours ago
0mins
Should l Buy DTIL?
Precision BioSciences announced that it has received two notices of allowance from the U.S. Patent and Trademark Office, or USPTO, for patent applications relating to the company's PBGENE-HBV program. The '136 application includes composition of matter claims that, when granted, will encompass the Arcus nuclease utilized in PBGENE-HBV. The '982 application includes composition of matter claims that, when granted, will encompass any polypeptide-including the PBGENE-HBV Arcus nuclease-that comprises a novel, shortened polypeptide linker developed by Precision. Future Arcus nucleases incorporating this novel polypeptide linker will also be covered by the granted claims.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DTIL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DTIL
Wall Street analysts forecast DTIL stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.350
Low
30.00
Averages
45.00
High
60.00
Current: 5.350
Low
30.00
Averages
45.00
High
60.00
About DTIL
Precision BioSciences, Inc. is a clinical-stage gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The Company's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The Company's iECURE-OTC program is developed in partnership with iECURE, Inc.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Precision BioSciences Secures Two Patent Allowances
- Patent Progress: Precision BioSciences has received two Notices of Allowance from the USPTO for its PBGENE-HBV program, which is expected to provide significant composition-of-matter protection for the ARCUS nuclease until 2044, thereby enhancing its competitive position in the Hepatitis B treatment market.
- Innovation Protection: The first patent application pertains to engineered meganucleases targeting the Hepatitis B virus genome, while the second covers polypeptide linkers for engineered meganucleases, ensuring intellectual property protection for future ARCUS nucleases and further solidifying the company's technological barriers.
- Clinical Trial Outlook: PBGENE-HBV is the first-in-human clinical trial targeting chronic Hepatitis B infection, aiming to eliminate cccDNA and potentially provide a curative treatment, with the FDA granting it Fast Track designation, indicating strong market anticipation for this therapy.
- Intellectual Property Strategy: The acquisition of these patents not only strengthens Precision's intellectual property portfolio but also provides overlapping patent coverage for the PBGENE-HBV program, ensuring the company has robust legal protection and market advantages in future R&D and commercialization efforts.
See More
Precision BioSciences Secures Two Patent Allowances
- Patent Progress: Precision BioSciences has received two Notices of Allowance from the USPTO for its PBGENE-HBV program, which is expected to provide significant protection for the ARCUS nuclease until 2044, thereby enhancing its competitive position in the Hepatitis B treatment market.
- Innovation Protection: The first patent application pertains to engineered meganucleases targeting the Hepatitis B virus genome, while the second covers polypeptide linkers for engineered meganucleases, ensuring broader intellectual property protection for future ARCUS nucleases and maintaining the uniqueness of its technology.
- Clinical Trial Outlook: PBGENE-HBV is the world's first clinical trial program targeting chronic Hepatitis B infection, aiming for potential cure by eliminating cccDNA, which is expected to significantly improve patient outcomes and drive the company's growth in the biopharmaceutical sector.
- FDA Fast Track Designation: The program has received Fast Track designation from the FDA, indicating its potential to meet high unmet medical needs, further boosting investor confidence in Precision BioSciences' future development.
See More
PBGENE-DMD Treatment Shows Durable Efficacy
- Preclinical Study Findings: PBGENE-DMD demonstrates significant muscle pathology improvements in a humanized DMD mouse model, with reductions of approximately 50-65% in CK levels at 90 days post-treatment, indicating substantial muscle integrity improvements and potential long-term treatment hope for DMD patients.
- Functional Improvements: Treated mice maintain approximately 81%-84% of maximal force output and 89%-92% of tetanic force output over nine months, showcasing the durability and efficacy of the treatment, supporting its potential as a one-time therapy aimed at long-term muscle function enhancement.
- Satellite Cell Editing: PBGENE-DMD promotes the restoration of functional muscle proteins across key muscle groups, including cardiac and skeletal muscles, through the editing of muscle satellite stem cells, with levels of functional dystrophin protein increasing over time, potentially providing sustained functional improvements for DMD patients.
- Clinical Trial Preparations: Precision BioSciences is preparing to initiate the Phase 1/2 FUNCTION-DMD clinical trial, expected to enroll DMD patients aged 2-7, aiming to evaluate the safety, tolerability, and efficacy of PBGENE-DMD, further validating its clinical application potential.
See More
Precision BioSciences' PBGENE-DMD Receives FDA Fast Track Designation
- Fast Track Designation: Precision BioSciences' investigational therapy PBGENE-DMD has received Fast Track designation from the FDA, aimed at accelerating the development of treatments for Duchenne muscular dystrophy, addressing significant unmet medical needs in this area.
- Regulatory Milestone: CEO Michael Amoroso stated that this designation represents an important regulatory milestone for PBGENE-DMD, highlighting the urgent need for effective treatments for patients suffering from Duchenne muscular dystrophy.
- Clinical Advancement: The Fast Track designation, along with the recent IND clearance, is expected to propel PBGENE-DMD's clinical investigation in boys with Duchenne muscular dystrophy, enhancing its competitive position in the market.
- Market Potential: With FDA support, PBGENE-DMD is poised to achieve positive outcomes in future clinical trials, providing a strong impetus for Precision BioSciences' growth in the rare disease sector.
See More
Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD
- Fast Track Designation: Precision BioSciences' PBGENE-DMD has received FDA Fast Track designation, aimed at expediting the development and review of treatments for Duchenne muscular dystrophy (DMD), highlighting the significant unmet medical need in this area.
- Clinical Study Plans: The company plans to host a virtual KOL event on March 17, 2026, to discuss PBGENE-DMD and its upcoming Phase 1/2 FUNCTION-DMD clinical study, which is expected to provide new treatment options for DMD patients.
- Technological Innovation: PBGENE-DMD utilizes a gene excision approach targeting mutations in exons 45-55, potentially offering durable functional muscle improvement for up to 60% of boys with DMD, showcasing its uniqueness and potential in the treatment landscape.
- Preclinical Research Results: In preclinical studies, PBGENE-DMD demonstrated significant functional improvements in a DMD mouse model, restoring function across cardiac, diaphragm, and various skeletal muscles, indicating its feasibility and efficacy for future clinical applications.
See More
FDA Grants Fast Track Designation to PBGENE-DMD for DMD Treatment
- Fast Track Designation: Precision BioSciences announced that its gene editing therapy PBGENE-DMD has received Fast Track designation from the FDA, aimed at expediting the development of treatments for Duchenne muscular dystrophy (DMD), highlighting the significant unmet medical need in this condition.
- Clinical Study Plans: The company plans to host a virtual webinar on March 17, 2026, to discuss the clinical utility of PBGENE-DMD and the upcoming Phase 1/2 FUNCTION-DMD clinical study, which is expected to provide new treatment options for DMD patients.
- Therapeutic Innovation: PBGENE-DMD utilizes a unique gene excision approach targeting mutations in exons 45-55 affecting 60% of DMD patients, designed to permanently edit the dystrophin gene through a single AAV vector encoding two ARCUS proteins, thereby restoring the production of functional muscle protein.
- Preclinical Study Results: In preclinical studies, PBGENE-DMD demonstrated significant functional improvements by restoring near full-length functional dystrophin protein across various muscle types, indicating its potential efficacy and long-term durability in treating DMD.
See More
Precision BioSciences Secures Two Patent Allowances
- Patent Progress: Precision BioSciences has received two Notices of Allowance from the USPTO for its PBGENE-HBV program, which is expected to provide significant composition-of-matter protection for the ARCUS nuclease until 2044, thereby enhancing its competitive position in the Hepatitis B treatment market.
- Innovation Protection: The first patent application pertains to engineered meganucleases targeting the Hepatitis B virus genome, while the second covers polypeptide linkers for engineered meganucleases, ensuring intellectual property protection for future ARCUS nucleases and further solidifying the company's technological barriers.
- Clinical Trial Outlook: PBGENE-HBV is the first-in-human clinical trial targeting chronic Hepatitis B infection, aiming to eliminate cccDNA and potentially provide a curative treatment, with the FDA granting it Fast Track designation, indicating strong market anticipation for this therapy.
- Intellectual Property Strategy: The acquisition of these patents not only strengthens Precision's intellectual property portfolio but also provides overlapping patent coverage for the PBGENE-HBV program, ensuring the company has robust legal protection and market advantages in future R&D and commercialization efforts.
See More
Precision BioSciences Secures Two Patent Allowances
- Patent Progress: Precision BioSciences has received two Notices of Allowance from the USPTO for its PBGENE-HBV program, which is expected to provide significant protection for the ARCUS nuclease until 2044, thereby enhancing its competitive position in the Hepatitis B treatment market.
- Innovation Protection: The first patent application pertains to engineered meganucleases targeting the Hepatitis B virus genome, while the second covers polypeptide linkers for engineered meganucleases, ensuring broader intellectual property protection for future ARCUS nucleases and maintaining the uniqueness of its technology.
- Clinical Trial Outlook: PBGENE-HBV is the world's first clinical trial program targeting chronic Hepatitis B infection, aiming for potential cure by eliminating cccDNA, which is expected to significantly improve patient outcomes and drive the company's growth in the biopharmaceutical sector.
- FDA Fast Track Designation: The program has received Fast Track designation from the FDA, indicating its potential to meet high unmet medical needs, further boosting investor confidence in Precision BioSciences' future development.
See More
PBGENE-DMD Treatment Shows Durable Efficacy
- Preclinical Study Findings: PBGENE-DMD demonstrates significant muscle pathology improvements in a humanized DMD mouse model, with reductions of approximately 50-65% in CK levels at 90 days post-treatment, indicating substantial muscle integrity improvements and potential long-term treatment hope for DMD patients.
- Functional Improvements: Treated mice maintain approximately 81%-84% of maximal force output and 89%-92% of tetanic force output over nine months, showcasing the durability and efficacy of the treatment, supporting its potential as a one-time therapy aimed at long-term muscle function enhancement.
- Satellite Cell Editing: PBGENE-DMD promotes the restoration of functional muscle proteins across key muscle groups, including cardiac and skeletal muscles, through the editing of muscle satellite stem cells, with levels of functional dystrophin protein increasing over time, potentially providing sustained functional improvements for DMD patients.
- Clinical Trial Preparations: Precision BioSciences is preparing to initiate the Phase 1/2 FUNCTION-DMD clinical trial, expected to enroll DMD patients aged 2-7, aiming to evaluate the safety, tolerability, and efficacy of PBGENE-DMD, further validating its clinical application potential.
See More
Precision BioSciences' PBGENE-DMD Receives FDA Fast Track Designation
- Fast Track Designation: Precision BioSciences' investigational therapy PBGENE-DMD has received Fast Track designation from the FDA, aimed at accelerating the development of treatments for Duchenne muscular dystrophy, addressing significant unmet medical needs in this area.
- Regulatory Milestone: CEO Michael Amoroso stated that this designation represents an important regulatory milestone for PBGENE-DMD, highlighting the urgent need for effective treatments for patients suffering from Duchenne muscular dystrophy.
- Clinical Advancement: The Fast Track designation, along with the recent IND clearance, is expected to propel PBGENE-DMD's clinical investigation in boys with Duchenne muscular dystrophy, enhancing its competitive position in the market.
- Market Potential: With FDA support, PBGENE-DMD is poised to achieve positive outcomes in future clinical trials, providing a strong impetus for Precision BioSciences' growth in the rare disease sector.
See More
Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD
- Fast Track Designation: Precision BioSciences' PBGENE-DMD has received FDA Fast Track designation, aimed at expediting the development and review of treatments for Duchenne muscular dystrophy (DMD), highlighting the significant unmet medical need in this area.
- Clinical Study Plans: The company plans to host a virtual KOL event on March 17, 2026, to discuss PBGENE-DMD and its upcoming Phase 1/2 FUNCTION-DMD clinical study, which is expected to provide new treatment options for DMD patients.
- Technological Innovation: PBGENE-DMD utilizes a gene excision approach targeting mutations in exons 45-55, potentially offering durable functional muscle improvement for up to 60% of boys with DMD, showcasing its uniqueness and potential in the treatment landscape.
- Preclinical Research Results: In preclinical studies, PBGENE-DMD demonstrated significant functional improvements in a DMD mouse model, restoring function across cardiac, diaphragm, and various skeletal muscles, indicating its feasibility and efficacy for future clinical applications.
See More
FDA Grants Fast Track Designation to PBGENE-DMD for DMD Treatment
- Fast Track Designation: Precision BioSciences announced that its gene editing therapy PBGENE-DMD has received Fast Track designation from the FDA, aimed at expediting the development of treatments for Duchenne muscular dystrophy (DMD), highlighting the significant unmet medical need in this condition.
- Clinical Study Plans: The company plans to host a virtual webinar on March 17, 2026, to discuss the clinical utility of PBGENE-DMD and the upcoming Phase 1/2 FUNCTION-DMD clinical study, which is expected to provide new treatment options for DMD patients.
- Therapeutic Innovation: PBGENE-DMD utilizes a unique gene excision approach targeting mutations in exons 45-55 affecting 60% of DMD patients, designed to permanently edit the dystrophin gene through a single AAV vector encoding two ARCUS proteins, thereby restoring the production of functional muscle protein.
- Preclinical Study Results: In preclinical studies, PBGENE-DMD demonstrated significant functional improvements by restoring near full-length functional dystrophin protein across various muscle types, indicating its potential efficacy and long-term durability in treating DMD.
See More
